Kazia Stock Analysis

KZIA
 Stock
  

USD 1.13  0.03  2.59%   

The big decline in price over the last few months for Kazia Therapeuticsmay raise some interest from investors. The stock closed today at a share price of 1.13 on 113,600 in trading volume. The company directors and management failed to add value to investors and position the firm supply of money to exploit market volatility in August. However, diversifying your holdings with Kazia Therapeutics or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.24. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Kazia Therapeutics partners.
Please see Correlation Analysis.
  
The Kazia Therapeutics stock analysis report makes it easy to digest most publicly released information about Kazia Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Kazia Stock analysis module also helps to analyze the Kazia Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Kazia Stock Analysis Notes

The company has price-to-book ratio of 0.46. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Kazia Therapeutics recorded a loss per share of 1.06. The entity had not issued any dividends in recent years. The firm had a split on the 14th of July 2017. Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Kazia Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about Kazia Therapeutics contact James Garner at 1300 787 272 or learn more at https://www.kaziatherapeutics.com.

Kazia Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Kazia Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Kazia Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Kazia Therapeutics generated a negative expected return over the last 90 days
Kazia Therapeutics has high historical volatility and very poor performance
Kazia Therapeutics may become a speculative penny stock
Kazia Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 15.19 M. Net Loss for the year was (15.08 M) with profit before overhead, payroll, taxes, and interest of 15.18 M.
Kazia Therapeutics currently holds about 15.19 M in cash with (8.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.15, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from www.cancertherapyadvisor.com: Management of Relapsed or Progressive Pediatric Low-Grade Glioma - Cancer Therapy Advisor

Kazia Therapeutics Upcoming and Recent Events

Earnings reports are used by Kazia Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Kazia Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report6th of January 2022
Next Fiscal Quarter End30th of September 2021
Next Fiscal Year End6th of October 2022
Last Quarter Report30th of June 2021
Last Financial Announcement30th of September 2020

Kazia Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Kazia Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Kazia Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Kazia Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.

Kazia Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Kazia Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kazia Therapeutics backward and forwards among themselves. Kazia Therapeutics' institutional investor refers to the entity that pools money to purchase Kazia Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Morgan StanleyCommon Shares201.6 K846 K
Citadel Advisors LlcCall Options63.7 K267 K
Envestnet Asset Management IncCommon Shares26.4 K111 K
Two Sigma Securities LlcCommon Shares24.7 K104 K
Citadel Advisors LlcCommon Shares22.8 K95 K
Sg Americas Securities LlcCommon Shares14 K59 K
Ubs Group AgCommon Shares2.5 K10 K
Simplex Trading LlcCommon Shares994K
Concourse Financial Group Securities IncPut Options0.00.0
Note, although Kazia Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Kazia Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 15.91 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kazia Therapeutics's market, we take the total number of its shares issued and multiply it by Kazia Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Kazia Profitablity

Kazia Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Kazia Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Kazia Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Kazia Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Kazia Therapeutics' profitability requires more research than a typical breakdown of Kazia Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (99.27) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (86.96) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.87.

Management Efficiency

The entity has return on total asset (ROA) of (19.59) % which means that it has lost $19.59 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (52.76) %, meaning that it created substantial loss on money invested by shareholders. Kazia Therapeutics management efficiency ratios could be used to measure how well kazia therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 27th of September, Kazia Therapeutics secures the mean deviation of 3.96, and Risk Adjusted Performance of (0.27). Kazia Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to collect and analyze data for nineteen technical drivers for Kazia Therapeutics, which can be compared to its peers in the industry. Please verify Kazia Therapeutics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Kazia Therapeutics is priced some-what accurately, providing market reflects its recent price of 1.13 per share. Given that Kazia Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Kazia Therapeutics Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Kazia Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Kazia Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Kazia Therapeutics Predictive Daily Indicators

Kazia Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Kazia Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Kazia Therapeutics Forecast Models

Kazia Therapeutics time-series forecasting models is one of many Kazia Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Kazia Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Kazia Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Kazia Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Kazia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Kazia Therapeutics. By using and applying Kazia Stock analysis, traders can create a robust methodology for identifying Kazia entry and exit points for their positions.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Kazia Therapeutics is traded on NASDAQ Exchange in the United States.

Current Kazia Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Kazia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Kazia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
18.0Strong Buy1Odds
Kazia Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Kazia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Kazia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Kazia Therapeutics, talking to its executives and customers, or listening to Kazia conference calls.
Kazia Analyst Advice Details

Kazia Stock Analysis Indicators

Kazia Therapeutics stock analysis indicators help investors evaluate how Kazia Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Kazia Therapeutics shares will generate the highest return on investment. By understating and applying Kazia Therapeutics stock analysis, traders can identify Kazia Therapeutics position entry and exit signals to maximize returns.
Quick Ratio2.01
Fifty Two Week Low1.1100
Revenue Growth754.70%
Shares Short Prior Month35.53k
Average Daily Volume Last 10 Day76.14k
Average Daily Volume In Three Month422.51k
Shares Percent Shares Out1.04%
Gross Margins100.00%
Float Shares9.79M
Fifty Two Week High12.2800
Enterprise Value To Ebitda-2.84
Fifty Day Average2.1320
Two Hundred Day Average5.5416
Enterprise Value To Revenue2.15
Please see Correlation Analysis. You can also try Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for analysis

When running Kazia Therapeutics price analysis, check to measure Kazia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kazia Therapeutics is operating at the current time. Most of Kazia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kazia Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kazia Therapeutics' price. Additionally, you may evaluate how the addition of Kazia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Kazia Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kazia Therapeutics. If investors know Kazia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kazia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kazia Therapeutics is measured differently than its book value, which is the value of Kazia that is recorded on the company's balance sheet. Investors also form their own opinion of Kazia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kazia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kazia Therapeutics' market value can be influenced by many factors that don't directly affect Kazia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kazia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Kazia Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kazia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.